Principles of Human Genetics¶
Chapter 479 | Part 16: Genes, the Environment, and Disease
KEY CLINICAL POINTS¶
- Genetics and genomics have revolutionized medicine by enabling personalized treatment, disease prevention, and understanding of complex disorders through genome-wide association studies (GWAS) and next-generation sequencing (NGS).
- The human genome consists of ~3 billion base pairs, with ~20,000 protein-coding genes, and epigenetic modifications (e.g., DNA methylation, histone acetylation) regulate gene expression.
- Mutations (single nucleotide polymorphisms, CNVs, trinucleotide expansions) underlie both monogenic disorders (e.g., cystic fibrosis, Huntington’s disease) and complex diseases (e.g., diabetes, cancer) through genetic and environmental interactions.
- Genetic testing, including whole exome/genome sequencing, is critical for diagnosing hereditary conditions, while ethical concerns like genetic privacy and discrimination are addressed by laws such as GINA.
- Precision medicine leverages genetic insights for targeted therapies (e.g., PARP inhibitors in BRCA-related cancers) and gene editing (CRISPR-Cas9) for conditions like sickle cell disease.
1. DEFINITION & OVERVIEW¶
Genetics studies individual genes and their inheritance, while genomics examines the entire genome and its interaction with environmental factors. The Human Genome Project enabled understanding of genetic basis of diseases, leading to advances in diagnostics, therapeutics, and personalized medicine. Genomics integrates DNA/RNA analysis with clinical data to improve disease management.
Table 479-1: Selected Databases for Genomics¶
| Database | URL | Description |
|---|---|---|
| National Center for Biotechnology Information (NCBI) | http://www.ncbi.nlm.nih.gov/ | Biomedical and genomic data, PubMed, sequence databases |
| Catalog of Published Genome-Wide Association Studies (GWAS) | https://www.ebi.ac.uk/gwas/ | High-resolution GWAS data |
| Online Mendelian Inheritance in Man (OMIM) | http://www.ncbi.nlm.nih.gov/omim | Compendium of Mendelian disorders |
| Genomes Online Database (GOLD) | http://www.genomesonline.org/ | Published/unpublished genome data |
| ENCODE | http://www.genome.gov/10005107 | Functional elements of the human genome |
1.1 Genetic vs. Genomic Medicine¶
Genetic medicine focuses on single-gene disorders (e.g., sickle cell anemia), while genomic medicine addresses complex traits (e.g., diabetes) through whole-genome analysis. Genomics enables identification of disease-associated variants, pharmacogenomics, and targeted therapies.
1.2 Epigenetics¶
Epigenetic modifications (DNA methylation, histone modifications) regulate gene expression without altering DNA sequence. Examples include X-chromosome inactivation and imprinting (e.g., Prader-Willi syndrome).
2. EPIDEMIOLOGY¶
Genetic disorders vary by inheritance pattern: autosomal dominant (e.g., Huntington’s), autosomal recessive (e.g., cystic fibrosis), X-linked (e.g., Duchenne muscular dystrophy), and mitochondrial. Complex disorders (e.g., diabetes, cancer) involve polygenic and environmental interactions.
Table 479-4: Indications for Cytogenetic Analysis¶
| Timing of Testing | Indications |
|---|---|
| Prenatal | Advanced maternal age, ultrasound abnormalities, maternal serum screening |
| Neonatal/Childhood | Multiple congenital anomalies, developmental delay, dysmorphic features |
| Adult | Infertility, recurrent miscarriage, familial cancer |
2.1 Inheritance Patterns¶
Autosomal dominant: 50% penetrance; autosomal recessive: 25% risk for offspring of carrier parents; X-linked: males more severely affected; mitochondrial: matrilineal transmission.
2.2 Population Prevalence¶
Monogenic disorders (e.g., sickle cell anemia) are more common in specific ethnic groups. Complex disorders (e.g., type 2 diabetes) show variable prevalence across populations due to gene-environment interactions.
3. GENETIC DISORDERS AND MUTATIONS¶
Mutations (single nucleotide variants, CNVs, trinucleotide repeats) cause monogenic and complex disorders. Examples include CFTR mutations in cystic fibrosis, BRCA1/2 in breast cancer, and Huntington’s disease (CAG repeats).
Table 479-5: Trinucleotide Repeat Disorders¶
| Disease | Locus | Repeat | Inheritance | Gene Product |
|---|---|---|---|---|
| Huntington’s Disease | 4p16.3 | CAG | AD | Huntingtin |
| Fragile X Syndrome | Xq27.3 | CGG | XR | FMR-1 protein |
| Myotonic Dystrophy | 19q13.32 | CTG | AD | Myotonin protein kinase |
| Friedreich’s Ataxia | 9q21.11 | GAA | AR | Frataxin |
3.1 Types of Mutations¶
Point mutations (e.g., CFTR ∆ F508), insertions/deletions (e.g., sickle cell β -globin mutation), chromosomal abnormalities (e.g., Down syndrome), and epigenetic changes (e.g., imprinting disorders).
4. GENETIC TESTING AND DIAGNOSTIC APPROACHES¶
Genetic testing includes linkage analysis, association studies, and NGS for monogenic and complex disorders. Prenatal testing (amniocentesis, CVS) and carrier screening are critical for high-risk populations.
Table 479-7: Genetic Approaches for Disease Gene Identification¶
| Method | Indications | Advantages | Limitations |
|---|---|---|---|
| Linkage Analysis | Monogenic disorders in families | Identifies susceptibility genes | Requires large pedigrees |
| GWAS | Complex traits (e.g., diabetes) | Unbiased, high-throughput | Requires large sample size |
| NGS | Rare/complex disorders | Comprehensive, cost-effective | Bioinformatic complexity |
4.1 Diagnostic Techniques¶
Linkage analysis for Mendelian disorders, GWAS for complex traits, and targeted sequencing for known genes (e.g., BRCA1/2). Whole-genome/exome sequencing identifies de novo mutations and CNVs.
4.2 Prenatal Diagnosis¶
Amniocentesis (16–20 weeks) and chorionic villus sampling (10–12 weeks) detect chromosomal abnormalities. Non-invasive prenatal testing (NIPT) analyzes maternal plasma DNA for fetal aneuploidy.
5. ETHICAL AND LEGAL ISSUES¶
Genetic privacy concerns, potential discrimination by insurers/employers, and ethical dilemmas in genetic testing (e.g., incidental findings). The Genetic Information Nondiscrimination Act (GINA) protects against misuse of genetic data.
5.1 Privacy and Discrimination¶
Genetic data is sensitive and must be protected. GINA prohibits health insurance discrimination based on genetic test results but does not cover employment discrimination.
5.2 Genetic Counseling¶
Counseling is essential for interpreting test results, managing anxiety, and guiding reproductive decisions. It addresses risks, inheritance patterns, and psychological impacts.
6. PRECISION MEDICINE AND FUTURE DIRECTIONS¶
Genomic insights enable targeted therapies (e.g., PARP inhibitors in BRCA-related cancers) and gene editing (CRISPR-Cas9) for monogenic disorders. Challenges include cost, data interpretation, and ethical concerns.
6.1 Therapeutic Applications¶
Gene therapy for Leber congenital amaurosis, spinal muscular atrophy, and hemophilia. CRISPR-based editing holds promise for curing genetic diseases like sickle cell anemia.
6.2 Challenges¶
High costs, technical complexity of NGS, and ethical issues in germline editing. Integration of genomic data into clinical practice requires robust bioinformatics and regulatory frameworks.